ArticlePituitary2026
Intranasal povidone-iodine concentration and olfactory recovery after endoscopic endonasal pituitary surgery.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe endoscopic endonasal approach (EEA) is a widely accepted, safe, and effective technique to treat pituitary lesions. Among postoperative considerations, olfactory function plays a key role in the patient’s quality of life. Although povidone-iodine (PVP-I) is widely used for intranasal antisepsis, its optimal concentration remains unclear. This study evaluated whether the PVP-I concentration during antisepsis influences postoperative olfactory recovery in patients undergoing EEA.
methodsWe retrospectively reviewed patients with sellar tumors who underwent endoscopic endonasal pituitary surgery at the Mackay Memorial Hospital (August 2015‒March 2022). Olfactory function was assessed using the Taiwan Smell Identification Test (TWSIT) at 1, 3, and 6 months postoperatively. Patients were stratified by the PVP-I concentration used: commercial aqueous 10% PVP-I and diluted 1% PVP-I.
resultsOf the 65 patients included, 57 had pituitary adenomas. Seventeen patients received 10% PVP-I during COVID-19 pandemic, and 48 received 1% PVP-I. Preoperative olfactory scores were comparable in both groups (1% vs. 10%: 40.9 ± 7.0 vs. 41.2 ± 5.9, p = 0.81). At 6 months, the mean TWSIT score in the 10% PVP-I group significantly decreased to 35.9 ± 9.5 (p = 0.03), whereas the 1% PVP-I group recovered to 40.5 ± 8.7, with no significant difference from baseline (p = 0.85). The intergroup difference in olfactory recovery was significant at 6 months postoperatively (p = 0.01). No patient developed postoperative wound infections or meningitis during follow-up in both groups.
conclusionBoth 10% and 1% PVP-I solutions were associated with excellent antiseptic outcomes. Patients receiving 1% PVP-I had better postoperative olfactory recovery than those receiving 10% PVP-I. Accordingly, diluted 1% PVP-I is recommended for nasal antisepsis to optimize olfactory outcomes in EEA.
Indexed as
Identifiers
41801467What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.